Novel angiogenic factors for predicting preeclampsia: sFlt-1, PlGF, and soluble endoglin

Open Clinical Chemistry Journal

Volumn 2, Issue , 2009, Pages 1-6

  Chen, Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

PlGF; Preeclampsia; sFlt 1; Soluble endoglin

Indexed keywords

ANGIOGENIC FACTOR; PRO ANGIOGENIC PROTEIN PLACENTAL GROWTH FACTOR; SOLUBLE ENDOGLIN; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOASSAY; MOLECULAR SIZE; NONHUMAN; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; SHORT SURVEY;

EID: 77953386273     PISSN: None     EISSN: 18742416     Source Type: Journal    
DOI: 10.2174/1874241600902010001     Document Type: Short Survey

References (62)

1. Walker, J.J. Pre-eclampsia. Lancet, 2000, 356(9237), 1260-1265.
2. Sibai, B.; Dekker, G.; Kupferminc, M. Pre-eclampsia. Lancet, 2005, 365(9461), 785-799.
3. Mutter, W.P.; Karumanchi, S.A. Molecular mechanisms of preeclampsia. Microvasc. Res., 2008, 75(1), 1-8.
4. Working group report on high blood pressure in pregnancy. National Institutes of Health. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program. NIH Publication No. 00-3029, revised July 2000.
5. Gu, Y.; Lewis, D.F.; Wang, Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor- 1, and placental growth factor in normal and preeclamptic pregnancies. J. Clin. Endocrinol. Metab., 2008, 93(1), 260-266.
6. Levine, R.J.; Thadhani, R.; Qian, C.; Lam, C.; Lim, K.H.; Yu, K.F.; Blink, A.L.; Sachs, B.P.; Epstein, F.H.; Sibai, B.M.; Sukhatme, V.P.; Karumanchi, S.A. Urinary placental growth factor and risk of preeclampsia. JAMA, 2005, 293(1), 77-85. (Pubitemid 40066702)
7. Roberts, J.M.; Gammill, H.S. Preeclampsia: recent insights. Hypertension, 2005, 46(6), 1243-1249.
8. Borzychowski, A.M.; Sargent, I.L.; Redman, C.W. Inflammation and pre-eclampsia. Semin. Fetal. Neonatal Med., 2006, 11(5), 309-316.
9. Makris, A.; Thornton, C.; Thompson, J.; Thomson, S.; Martin, R.; Ogle, R.; Waugh, R.; McKenzie, P.; Kirwan, P.; Hennessy, A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int., 2007, 71(10), 977-984. (Pubitemid 46741987)
10. Bdolah, Y.; Karumanchi, S.A.; Sachs, B.P. Recent advances in understanding of preeclampsia. Croat. Med. J., 2005, 46(5), 728-736.
11. Thadhani, R.; Mutter, W.P.; Wolf, M.; Levine, R.J.; Taylor, R.N.; Sukhatme, V.P.; Ecker, J.; Karumanchi, S.A. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab., 2004, 89(2), 770-775. (Pubitemid 38269892)
12. Shibuya, M.; Yamaguchi, S.; Yamane, A.; Ikeda, T.; Tojo, A.; Matsushime, H.; Sato, M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene, 1990, 5(4), 519-524. (Pubitemid 20137063)
13. Matthews, W.; Jordan, C.T.; Gavin, M.; Jenkins, N.A.; Copeland, N.G.; Lemischka, I.R. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. USA, 1991, 88(20), 9026-9030. (Pubitemid 21915561)
14. Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis, 2006, 9(4), 225-230.
15. Kita, N.; Mitsushita, J. A possible placental factor for preeclampsia: sFlt-1. Curr. Med. Chem., 2008, 15(7), 711-715.
16. Kendall, R.L.; Wang, G.; Thomas, K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun., 1996, 226(2), 324-328. (Pubitemid 26331903)
17. Fong, G.H.; Rossant, J.; Gertsenstein, M.; Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 1995, 376(6535), 66-70.
18. Fong, G.H.; Zhang, L.; Bryce, D.M.; Peng, J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development, 1999, 126(13), 3015-3025. (Pubitemid 29355693)
19. Barleon, B.; Sozzani, S.; Zhou, D.; Weich, H.A.; Mantovani, A.; Marmé, D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood, 1996, 87(8), 3336-3343. (Pubitemid 26115364)
20. Bussolati, B.; Dunk, C.; Grohman, M.; Kontos, C.D.; Mason, J.; Ahmed, A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am. J. Pathol., 2001, 159(3), 993-1008. (Pubitemid 32847190)
21. He, Y.; Smith, S.K.; Day, K.A.; Clark, D.E.; Licence, D.R.; Charnock- Jones, D.S. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol. Endocrinol., 1999, 13(4), 537-545. (Pubitemid 30636421)
22. Zhou, Y.; McMaster, M.; Woo, K.; Janatpour, M.; Perry, J.; Karpanen ,T.; Alitalo, K.; Damsky, C.; Fisher, S.J. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol., 2002, 160(4), 1405-1423. (Pubitemid 34411644)
23. Karumanchi, S.A.; Epstein, F.H. Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Kidney Int., 2007, 71(10), 959-961. (Pubitemid 46742004)
24. Maynard, S.E.; Min, J.Y.; Merchan, J.; Lim, K.H.; Li, J.; Mondal, S.; Libermann, T.A.; Morgan, J.P.; Sellke, F.W.; Stillman, I.E.; Epstein, F.H.; Sukhatme, V.P.; Karumanchi, S.A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest., 2003, 111(5), 649-658. (Pubitemid 36278583)
25. Ahmad, S.; Ahmed, A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res., 2004, 95(9), 884-891. (Pubitemid 39435003)
26. Kitamoto, Y.; Takeya, M.; Tokunaga, H.; Tomita, K. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku. J. Exp. Med., 2001, 195(1), 43-54. (Pubitemid 34036885)
27. Sugimoto, H.; Hamano, Y.; Charytan, D.; Cosgrove, D.; Kieran, M.; Sudhakar, A.; Kalluri, R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem., 2003, 278(15), 12605-12608. (Pubitemid 36800018)
28. Yang, J.C.; Haworth, L.; Sherry, R.M.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Steinberg, S.M.; Chen, H.X.; Rosenberg, S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 2003, 349(5), 427-434. (Pubitemid 36910021)
29. Glusker, P.; Recht, L.; Lane, B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med., 2006, 354(9), 980-982. (Pubitemid 43313687)
30. Hirashima, C.; Ohkuchi, A.; Arai, F.; Takahashi, K.; Suzuki, H.; Watanabe, T.; Kario, K.; Matsubara, S.; Suzuki, M. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens. Res., 2005, 28(9), 727-732. (Pubitemid 41723531)
31. Levine, R.J.; Maynard, S.E.; Qian, C.; Lim, K.H.; England, L.J.; Yu, K.F.; Schisterman, E.F.; Thadhani, R.; Sachs, B.P.; Epstein, F.H.; Sibai, B.M.; Sukhatme, V.P.; Karumanchi, S.A. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med., 2004, 350(7), 672-683. (Pubitemid 38364626)
32. Chaiworapongsa, T.; Romero, R.; Espinoza, J.; Bujold, E.; Mee Kim, Y.; Gonçalves, L.F.; Gomez, R.; Edwin, S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am. J. Obstet. Gynecol., 2004, 190(6), 1541-1547. (Pubitemid 39006187)
33. Widmer, M.; Villar, J.; Benigni, A.; Conde-Agudelo, A.; Karumanchi, S.A.; Lindheimer, M. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet. Gynecol., 2007, 109(1), 168-180. (Pubitemid 46035522)
34. Moore Simas, T.A.; Crawford, S.L.; Solitro, M.J.; Frost, S.C.; Meyer, B.A.; Maynard, S.E. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol., 2007, 197(3), 244.el-8. (Pubitemid 47361967)
35. Salahuddin, S.; Lee, Y.; Vadnais, M.; Sachs, B.P.; Karumanchi, S.A.; Lim, K.H. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am. J. Obstet. Gynecol., 2007, 197(1), 28.e1-6
36. Iyer, S.; Leonidas, D.D.; Swaminathan, G.J.; Maglione, D.; Battisti, M.; Tucci, M.; Persico, M.G.; Acharya, K.R. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. J. Biol. Chem., 2001, 276(15), 12153-12161. (Pubitemid 37385382)
37. Yang, W.; Ahn, H.; Hinrichs, M.; Torry, R.J.; Torry, D.S. Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J. Reprod. Immunol., 2003, 60(1), 53-60. (Pubitemid 37272295)
38. Park, J.E.; Chen, H.H.; Winer, J.; Houck, K.A.; Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem., 1994, 269(41), 25646-25654. (Pubitemid 24982909)
39. Autiero, M.; Waltenberger, J.; Communi, D.; Kranz, A.; Moons, L.; Lambrechts, D.; Kroll, J.; Plaisance, S.; De Mol, M.; Bono, F.; Kliche, S.; Fellbrich, G.; Ballmer-Hofer, K.; Maglione, D.; Mayr- Beyrle, U.; Dewerchin, M.; Dombrowski, S.; Stanimirovic, D.; Van Hummelen, P.; Dehio, C.; Hicklin, D.J.; Persico, G.; Herbert, J.M.; Communi, D.; Shibuya, M.; Collen, D.; Conway, E.M.; Carmeliet, P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med., 2003, 9(7), 936-943. (Pubitemid 36889938)
40. Autiero, M.; Luttun, A.; Tjwa, M.; Carmeliet, P. Placental growth factor and its receptor, vascular endothelial growth factor receptor- 1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J. Thromb. Haemost., 2003, 1(7), 1356-1370.
41. Maglione, D.; Guerriero, V.; Viglietto, G.; Delli-Bovi, P.; Persico, M.G. Isolation of a human placenta cDNA coding for a protein re lated to the vascular permeability factor. Proc. Natl. Acad. Sci. USA, 1991, 88(20), 9267-9271. (Pubitemid 21915612)
42. Torry, D.S.; Mukherjea, D.; Arroyo, J.; Torry, R.J. Expression and function of placenta growth factor: implications for abnormal placentation. J. Soc. Gynecol. Investig., 2003, 10(4), 178-188. (Pubitemid 36579239)
43. Levine, R.J.; Lam, C.; Qian, C.; Yu, K.F.; Maynard, S.E.; Sachs, B.P.; Sibai, B.M.; Epstein, F.H.; Romero, R.; Thadhani, R.; Karumanchi, S.A.; CPEP Study. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med., 2006, 355(10), 992-1005. (Pubitemid 44343543)
44. Quackenbush, E.J.; Letarte, M. Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies. J. Immunol., 1985, 134(2), 1276-1285. (Pubitemid 15158627)
45. Gougos, A.; Letarte, M. Primary structure of endoglin, an RGDcontaining glycoprotein of human endothelial cells. J. Biol. Chem., 1990, 265(15), 8361-8364. (Pubitemid 20167332)
46. Bellón, T.; Corbí, A.; Lastres, P.; Calés, C.; Cebrián, M.; Vera, S.; Cheifetz, S.; Massague, J.; Letarte, M.; Bernabéu, C. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol., 1993, 23(9), 2340-2345. (Pubitemid 23265903)
47. Barbara, N.P.; Wrana, J.L.; Letarte, M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J. Biol. Chem., 1999, 274(2), 584-594. (Pubitemid 129535212)
48. Luft, F.C. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol. Dial. Transplant., 2006, 21(11), 3052-3054. (Pubitemid 44567075)
49. Cheifetz, S.; Bellón, T.; Calés, C.; Vera, S.; Bernabeu, C.; Massagué, J.; Letarte, M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem., 1992, 267(27), 19027-19030.
50. Gougos, A.; St Jacques, S.; Greaves, A.; O'Connell, P.J.; d'Apice, A.J.; Bühring, H.J.; Bernabeu, C.; van Mourik, J.A.; Letarte, M. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int. Immunol., 1992, 4(1), 83-92.
51. Lastres, P.; Bellon, T.; Cabañas, C.; Sanchez-Madrid, F.; Acevedo, A.; Gougos, A.; Letarte, M.; Bernabeu, C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur. J. Immunol., 1992, 22(2), 393-397.
52. Chen, C.Z.; Li, M.; de Graaf, D.; Monti, S.; Göttgens, B.; Sanchez, M.J.; Lander, E.S.; Golub, T.R.; Green, A.R.; Lodish, H.F. Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc. Natl. Acad. Sci. USA, 2002, 99(24), 15468-15473. (Pubitemid 35403957)
53. Dallas, N.A.; Samuel, S.; Xia, L.; Fan, F.; Gray, M.J.; Lim, S.J.; Ellis, L.M. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin. Cancer Res., 2008, 14(7), 1931-1937
54. ten Dijke, P.; Goumans, M.J.; Pardali, E. Endoglin in angiogenesis and vascular diseases. Angiogenesis, 2008, 11(1), 79-89.
55. Raab, U.; Velasco, B.; Lastres, P.; Letamendía, A.; Calés, C.; Langa, C.; Tapia, E.; López-Bote, J.P.; Páez, E.; Bernabéu, C. Expression of normal and truncated forms of human endoglin. Biochem. J., 1999, 339(Pt 3), 579-588. (Pubitemid 29243521)
56. Venkatesha, S.; Toporsian, M.; Lam, C.; Hanai, J.; Mammoto, T.; Kim, Y.M.; Bdolah, Y.; Lim, K.H.; Yuan, H.T.; Libermann, T.A.; Stillman, I.E.; Roberts, D.; D'Amore, P.A.; Epstein, F.H.; Sellke, F.W.; Romero, R.; Sukhatme, V.P.; Letarte, M.; Karumanchi, S.A. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med., 2006, 12(6), 642-649. (Pubitemid 43865232)
57. Masuyama, H.; Nakatsukasa, H.; Takamoto, N.; Hiramatsu, Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J. Clin. Endocrinol. Metab., 2007, 92(7), 2672-2679. (Pubitemid 47037375)
58. Stepan, H.; Krämer, T.; Faber, R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J. Clin. Endocrinol. Metab., 2007, 92(7), 2831-2834. (Pubitemid 47037397)
59. Rana, S.; Karumanchi, S.A.; Levine, R.J.; Venkatesha, S.; Rauh- Hain, J.A.; Tamez, H.; Thadhani, R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension, 2007, 50(1), 137-142. (Pubitemid 46986022)
60. Robinson, C.J.; Johnson, D.D. Soluble endoglin as a secondtrimester marker for preeclampsia. Am. J. Obstet. Gynecol., 2007, 197(2), 174.e1-5 (Pubitemid 47198172)
61. Baumann, M.U.; Bersinger, N.A.; Mohaupt, M.G.; Raio, L.; Gerber, S.; Surbek, D.V. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am. J. Obstet. Gynecol., 2008, 199(3), 266.e1-6
62. Stepan, H.; Geipel, A.; Schwarz, F.; Krämer, T.; Wessel, N.; Faber, R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol., 2008, 198(2), 175.e1-6